Related Experiment Video
Updated: Feb 7, 2026

Rapid Development of Cell State Identification Circuits with Poly-Transfection
Published on: February 24, 2023
Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy
Christophe Sandt1, Olivier Feraud2, Marie-Laure Bonnet2
1SOLEIL Synchrotron, Saint Aubin, 91192, Gif sur Yvette, France.
Abstract:
Despite the major success obtained by the use of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML), resistances to therapies occur due to mutations in the ABL-kinase domain of the BCR-ABL oncogene. Amongst these mutations, the "gatekeeper" T315I is a major concern as it renders leukemic cells resistant to all licenced TKI except Ponatinib. We report here that Fourier transform infrared (FTIR) microspectroscopy is a powerful methodology allowing rapid and direct identification of a spectral signature in single cells expressing T315I-mutated BCR-ABL. The specificity of this spectral signature is confirmed using a Dox-inducible T315I-mutated BCR-ABL-expressing human UT-7 cells as well as in murine embryonic stem cells. Transcriptome analysis of UT-7 cells expressing BCR-ABL as compared to BCR-ABL T315I clearly identified a molecular signature which could be at the origin of the generation of metabolic changes giving rise to the spectral signature. Thus, these results suggest that this new methodology can be applied to the identification of leukemic cells harbouring the T315I mutation at the single cell level and could represent a novel early detection tool of mutant clones. It could also be applied to drug screening strategies to target T315I-mutated leukemic cells.
Insights
Fourier transform infrared (FTIR) microspectroscopy rapidly identifies the T315I mutation in chronic myeloid leukemia (CML) cells. This technique offers a new tool for early detection and drug screening of resistant CML.
Area of Science:
- Biomedical Spectroscopy
- Oncology
- Molecular Biology
Background:
- Tyrosine kinase inhibitors (TKI) are successful in treating chronic myeloid leukemia (CML).
- Therapy resistance in CML can arise from mutations in the BCR-ABL oncogene's ABL-kinase domain.
- The T315I mutation, a "gatekeeper" mutation, confers resistance to most TKIs, except Ponatinib.
Purpose of the Study:
- To investigate Fourier transform infrared (FTIR) microspectroscopy as a method for identifying the T315I mutation in BCR-ABL.
- To explore the potential of FTIR microspectroscopy for early detection and drug screening in CML.
Main Methods:
- Utilized Fourier transform infrared (FTIR) microspectroscopy for single-cell analysis.
- Employed Dox-inducible T315I-mutated BCR-ABL-expressing human UT-7 cells and murine embryonic stem cells for validation.
- Performed transcriptome analysis to identify molecular signatures associated with the T315I mutation.
Main Results:
- FTIR microspectroscopy successfully identified a unique spectral signature in single cells expressing the T315I-mutated BCR-ABL.
- The specificity of the spectral signature was confirmed in engineered cell lines.
- Transcriptome analysis revealed molecular differences linked to metabolic changes underlying the observed spectral signature.
Conclusions:
- FTIR microspectroscopy is a powerful tool for rapid, single-cell identification of the T315I BCR-ABL mutation.
- This methodology holds promise as a novel early detection tool for CML mutant clones.
- The technique can potentially be applied to drug screening strategies targeting T315I-mutated CML cells.
More Related Videos
12:04Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
08:53Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Cell Specific Gene Expression
Mutation, Gene Flow, and Genetic Drift
Cancers Originate from Somatic Mutations in a Single Cell